Loading company details...
Beta
Latest Form 4 (Sep 21, 2026): Karen Akinsanya (President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships): Exercise/Conversion of 31,599 shares, $137.1K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 21, 2026 | Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships | Exercise/Conversion | 31,599 | $137.1K |
| Jul 17, 2026 | Rachit Jain, EVP & CFO | Sale | 875 | $13.6K |
| Jun 29, 2026 | Richard Friesner | Gift | 679,373 | n/a |
| Jun 23, 2026 | Arun Oberoi | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Jeffrey Chodakewitz | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Richard Friesner | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Gary L. Ginsberg | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Rosana Kapeller-Libermann | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Michael Lynton | Grant/Award | 8,141 | n/a |
| Jun 23, 2026 | Gary Sender | Grant/Award | 8,141 | n/a |